Abstract: The present disclosure relates to methods and systems for assessing the risk of a human subject for developing colorectal cancer. These methods may be combined with the subjects clinical risk to improve risk analysis. Such methods may be used to assist decision making about appropriate colorectal cancer screening regimens.

Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilizing the radiolabelled compounds of the invention.

Abstract: The present disclosure provides a quantum processor realized in a semiconductor material and method to operate the quantum processor to implement adiabatic quantum computation. The quantum processor comprises a plurality of qubit elements disposed in a two-dimensional matrix arrangement. The qubits are implemented using the nuclear or electron spin of phosphorus donor atoms. Further, the processor comprises a control structure with a plurality of control members, each arranged to control a plurality of qubits disposed along a line or a column of the matrix. The control structure is controllable to perform adiabatic quantum error corrected computation.

Abstract: The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.

Abstract: The present disclosure provides a quantum processor realized in a semiconductor material and method to operate the quantum processor to implement error corrected quantum computation. The quantum processor comprises a plurality of qubit elements disposed in a two-dimensional matrix arrangement. The qubits are implemented using the nuclear or electron spin of phosphorus donor atoms. Further, the processor comprises a control structure with a plurality of control members, each arranged to control a plurality of qubits disposed along a line or a column of the matrix. The control structure is controllable to perform topological quantum error corrected computation.

Abstract: The present invention relates generally to polysaccharide synthases. More particularly, the present invention relates to (1,3;1,4)-?-D-glucan synthases. The present invention provides, among other things, methods for influencing the level of (1,3;1,4)-?-D-glucan produced by a cell and nucleic acid and amino acid sequences which encode (1,3;1,4)-?-D-glucan synthases.

Abstract: The disclosure relates to biodegradable polyether network polymers crosslinked via ester linkages, to substrates, implants and scaffolds comprising the biodegradable polyether network polymers, to methods for preparing such network polymers, implants and scaffolds, and to methods of using substrates, implants and scaffolds comprising the network polymers, particularly for culturing cells and regenerating tissue.

Abstract: The present disclosure provides a method of fabricating a diamond membrane. The method comprises providing a substrate and a support structure. The substrate comprises a diamond material having a first surface and the substrate further comprises a sub-surface layer that is positioned below the first surface and has a crystallographic structure that is different to that of the diamond material. The sub-surface layer is positioned to divide the diamond material into first and second regions wherein the first region is positioned between the first surface and the sub-surface layer. The support structure also comprises a diamond material and is connected to, and covers a portion of, the first surface of the substrate. The method further comprises selectively removing the second region of the diamond material from the substrate by etching away at least a portion of the sub-surface layer of the substrate.

Abstract: The present invention relates to a gas separation membrane for separating a target gas species from a mixture of gas species, the membrane comprising: (i) a porous substrate having a first and second surface region between which the mixture of gas species will flow; (ii) a sealing polymer layer of different composition to the porous substrate that (a) forms a continuous coating across the second surface region of the substrate, and (b) is permeable to the mixture of gas species; and (iii) a selective polymer layer in the form of a cross linked macromolecular film that (a) is located on and covalently coupled to the sealing polymer layer, and (b) has a higher permeability to the target gas species relative to other gas species present in the mixture of gas species that is to be subjected to separation.

Abstract: The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.

Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.

Abstract: A protocol for pain management includes a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol includes the use of a CCL17 signaling antagonist alone or in combination with another analgesic compound to treat pain associated with inflammatory conditions. The CCL17 signaling antagonist includes an antibody or antigen-binding derivative thereof which binds to CCL17 or its receptor.

Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.

Abstract: The invention described herein relates to a method of detecting malaria comprising the steps of: (i) delivering an evanescent IR beam through said ATR substrate in contact with a patient blood sample; (ii) detecting IR radiation transmitted from the ATR substrate to produce a signal characteristic for one or more lipids in the sample, and (iii) processing said signal and a set of reference library spectra of lipids associated with malaria parasites in order to detect matches and quantify said one or more lipids in the sample. In contrast to the prior art, the present invention relies on detecting lipids instead of hemozoin.

Abstract: The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.

Abstract: A method of delivery of fluid through a computer controlled fluid network, the network including; regulators to control the flow of fluid to deliver a predetermined amount thereof to at least one customer; a first control system for opening and closing the regulators, which collects data based on timed measurements of fluid levels upstream and downstream of respective regulators and the opening positions of respective regulators, using data analysis to provide models for prediction of fluid levels between regulators; a second control system that is a supervisory layer interacting with the first control system to provide adjustments to the controlling of the regulators based on constraint and future flow load; and a third control system interacting with the first and second control systems, which processes fluid delivery requests from the at least one customer to provide a flow load delivery schedule based on the hydraulic capacity of the network.

Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.

Abstract: The present invention relates to chlorine resistant polyelectrolyte multilayer membranes which can be used as reverse osmosis, forward osmosis or nanofiltration membranes for applications such as desalination and water purification and methods of making membranes of this type.

Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.

Abstract: Methods and kits for the diagnosis of illnesses related to protocadherin 19 (PCDH 19) protein deficiency or altered PCDH 19 protein function, in particular EFMR (Epilepsy and Mental Retardation limited to Females) are provided, as well as methods and kits for the identification of a predisposition to such illnesses and methods of screening subjects to identify carriers of such illnesses and methods and kits for the therapeutic or prophylactic treatment of PCDH 19 deficiency or altered PCDH 19 protein function. Further, nucleotide and amino acid sequences corresponding to a complete PCDH19 open reading frame (ORF), mutant sequences encoding non-functional PCDH19 mRNA or altered PCDH19 mRN A are described along with transformed cells and non-human transgenic animals comprising wild-type or mutant PCDH19 ORF nucleotide sequences.